Diabetes and Obesity Peptides

Overview

Lately, significant progress has been made in diabetes and obesity treatment by developing drugs focused on Glucagon-like Peptide 1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) and their Receptors.

Glucagon-like Peptide 1 (GLP-1)

GLP-1 is an incretin hormone secreted by the gut in response to food intake. It enhances glucose-dependent insulin secretion, which helps regulate blood sugar levels. GLP-1 also suppresses appetite, slows gastric emptying, and promotes satiety. Clinically, GLP-1 receptor agonists (GLP-1RAs) are used to treat type 2 diabetes and have emerged as effective weight loss agents. These drugs mimic endogenous GLP-1, promoting insulin release and reducing appetite.

Glucose-Dependent Insulinotropic Polypeptide (GIP)

GIP is another incretin hormone released after meals. Unlike GLP-1, GIP primarily stimulates insulin secretion but has minimal effects on appetite. GIP receptors (GIPRs) are structurally similar to GLP-1 receptors. Dual agonists targeting both GLP-1 and GIP receptors can prevent fat storage and enhance weight loss.

Understanding the roles of GLP-1 and GIP peptides and their receptors is crucial for developing effective weight loss medications. These insights pave the way for innovative therapies that address obesity and its associated comorbidities.

GenScript offers high quality off-the-shelf peptides for diabetes and obesity research. Our strong custom peptide synthesis capabilities can support your research if you need modified or conjugation-ready peptides.